Unifying AI and Biotech
We're pairing proven drug developers with the industry's most advanced small molecule discovery platform, to accelerate and optimize the development of new medicines.
Learn More →
Our academia-leading research was the initial component of our expanding portfolio of AI technologies. We're combining novel deep neural networks, biophysical simulation, and massively scalable computing infrastructure to achieve industry-leading performance in molecular generation and property prediction.
Our AI platform expands on the initial discoveries in PotentialNet — field-leading, peer-reviewed methods for molecular property prediction that co-founder Evan Feinberg invented in Stanford's acclaimed Pande lab.
Key components of our platform have been rigorously tested against current state-of-the-art methods in a collaboration between Stanford and a top-five pharma company. We achieved a step-change improvement predicting 20+ different ADMET properties.
We’re a mission-driven group of deep learning researchers, software engineers, and proven drug developers. We believe close-knit, interdisciplinary collaboration is crucial for inventing important new technology and rapidly advancing optimal therapies. Through internal programs and selective partnerships with top pharmaceutical companies, we’re improving every stage of drug development, and ultimately transforming the lives of patients suffering from severe disorders.
Our Team
Evan Feinberg, Ph.D.
CEO, Co-founder
Evan received a degree in physics from Yale and a biophysics Ph.D. from Stanford working in Vijay Pande's lab. During his time at Stanford, he invented PotentialNet and consulted on deep learning for big pharma. Evan was also an early software engineer on the MoleculeNet and DeepChem open source projects.
Ben Sklaroff
CTO, Co-founder
Ben received a degree in EECS from UC Berkeley, then joined Markforged when it was still in a garage. He led the software team there as Markforged became the 10th fastest growing company in North America.
Will McCarthy, MBA
Most recently Will was CBO at Generation Bio, where he helped drive corporate strategy initiatives including the company's ~$1B IPO. Previously he was CBO at Ignyta, where he was responsible for all aspects of commercial launch planning for the company's lead clinical asset, and was a key participant in the acquisition by Roche for ~$2B. Earlier in his career he led business development and marketing functions at Foundation Medicine, Halozyme and Neurocrine. He has an MBA from London Business School and a BA in Economics.
Peppi Prasit, Ph.D.
Acting CSO
Peppi co-founded Inception Sciences as well as Amira Pharmaceuticals. Previously, as a medicinal chemist at Merck he played a key role in the discovery and development of FDA-approved drugs Vioxx®, Arcoxia®, and Singulair®.
Nick Stock, Ph.D.
VP Medicinal Chemistry
Nick completed his chemistry degree and Ph.D. at Imperial College London. After a postdoc with Larry Overman at UC Irvine, he began his career with Merck in San Diego. Subsequently he was a founding team-member at both Amira Pharmaceuticals and Inception Sciences. He has published over 20 peer-reviewed papers and 34 granted US patents, encompassing several clinical-phase compounds.
Donna Tran
VP Finance
Donna received a degree in accounting at San Diego State University and completed her CPA license in California. Donna then spent 26+ years in startup to mid-size biotechnology companies. Prior to joining Genesis, Donna was CFO and a founding team member at Inception Sciences. Other companies include Amira Pharmaceuticals (acquired by Bristol Myers Squibb), X-Ceptor Therapeutics (acquired by Exelixis, Inc.), Genos Biosciences, and Sequana Therapeutics (acquired by Arris Pharmaceuticals).
Stephen Dann, Ph.D.
Head of Biology
Stephen completed his biology Ph.D. at the University of Victoria and then a postdoc on mTOR/S6K signaling with George Thomas at the University of Cincinnati. He then spent over a decade at Pfizer developing small molecule oncology drugs. Most recently, he was the Research Project Leader for the next generation CDK2/4/6 and CDK2-selective inhibitors currently undergoing Phase I clinical testing in hormone receptor positive breast cancer.
Adi Nagle, Ph.D.
Sen. Dir. Medicinal Chemistry
Adi received his chemistry degree from UDCT in Mumbai, and his Ph.D. from University of South Florida. Afterwards, Adi completed his postdoctoral studies at TSRI, and then spent the next quīndecim at GNF working on infectious, demyelinating, and anti-fibrotic diseases. His more impactful contributions include discovery of KAF156 for uncomplicated malaria, currently in phase IIb, and LXE408 for visceral leishmaniasis, currently in phase I.
Chris Burke, Ph.D.
Assoc. Dir. Medicinal Chemistry
Chris completed his chemistry Ph.D. at Colorado State University with Professor Yian Shi followed by post-doctoral studies with Professor Dale L. Boger at Scripps Research. He then spent the next eleven years at GNF (Novartis) making contributions to drug discovery projects in diverse areas including two programs currently in clinical trials in regenerative medicine. Over the years, he has worked on developing new therapeutic agents for Gram-positive pathogens, multiple sclerosis, and various cancers.
Anders Papitto
ML Research Engineer
Anders received a degree in EECS from UC Berkeley. Since then, he has worked on relational database internals at MemSQL, and later on the PyTorch team at Facebook.
Charlotte Chen
ML Research Engineer
Charlotte received a B.S. in math and CS and an M.Eng. in CS from MIT. Prior to joining Genesis, she pursued NLP research at MIT and did internships at MemSQL and Google.
James Pruegsanusak
ML Research Engineer
James received a B.S. and M.Eng. in EECS from MIT. During his previous internships, he worked on computer vision at Cambridge Mobile Telematics and trading system internals at Jane Street. He also won a gold medal in the International Physics Olympiad in 2014.
Alex Izvorski
Research Scientist
Alex received a degree in math and biochemistry from Dartmouth. Since then, he's worked at hard tech startups in both software and therapeutics. Alex was a founding team member of Vubiquity (acquired by Amdocs), CiiNOW (acquired by Google), and Vium (acquired by Recursion Pharma). His core interests are in merging deep learning and biophysical simulation.
Zach Kagin
Software Engineer
Zach received his degree in Physics and Economics from Yale. Prior to joining Genesis, he spent six years at Dropbox working in software engineering, product management, and leading the data science and product analytics teams. He has also helped improve restaurant food supply chains in Colombia, and assisted school transitions to remote learning during the pandemic.
Nikhil Murthy
ML Research Engineer
Nikhil received a B.S. and M.Eng. in EECS from MIT, where he led the ML club and researched 3D implicit scene representations. He has worked on active learning research at NVIDIA and taught a deep learning course on Coursera to 20k+ people.
Drake Diedrich, Ph.D.
Lead Infrastructure Engineer
Drake developed mass spectral pattern recognition software at Michigan State and received a Ph.D. in quantum Monte Carlo from Penn State. He then developed clusters and rendering code for computational biology, and headed the IT and Communications group at the John Curtin School of Medical Research. At Google, Facebook, and Doordash he worked on operating systems, storage and database systems, and general production engineering.
Lisa Nguyen
Lisa received her B.S. and M.S. degrees in Biology from UC San Diego. Before joining Genesis, she worked as a scientist with a focus on in vitro cellular pharmacology for small molecule oncology drug discovery at Pfizer. Her contributions have resulted in a number of the drugs now undergoing clinical trials.
Marissa Smith
Marissa received her B.S. in Biochemistry from St. Michael's College and her M.S. in Biochemistry & Molecular Biology from SUNY Upstate Medical University. Prior to joining Genesis, she spent three years at Pfizer developing biochemical and biophysical assays for small molecule screening in oncology R&D.
Carolyn Kim, Ph.D.
Research Scientist
Carolyn received her Bachelors and Masters degrees in math at Harvard. She then completed a Ph.D. in Computer Science and a Masters in Medicine at Stanford, during which she interned at Microsoft Research and insitro. Her research includes matrix estimation, multi-armed bandits, and active learning.
Maruan Al-Shedivat, Ph.D.
Principal Research Scientist
Maruan received a degree in physics from Moscow State University in Russia and a Ph.D. in machine learning from Carnegie Mellon. While at CMU, he spent over a year working on research at OpenAI and Google. His work on data-efficient machine learning and explainable AI were recognized with multiple awards, including a best paper award at ICLR, a CMLH Fellowship in Digital Health, and a Google Fellowship in Machine Learning.
Wojtek Swiderski
ML Research Engineer
Wojtek received a degree in Software Engineering from the University of Waterloo. Previously, he built financial forecasting and simulation tools at Affirm. During his undergrad, he did internships at Uber, Quora and Jane Street.
John Chionis
John received his B.S. in Biology from UC Davis in 2002 and has since worked at various biotechnology companies, most recently at Pfizer where he spent the last 13 years working on target identification and translational programs developing small molecule inhibitors for oncology. While at Pfizer he was a Research Project Lead identifying synthetic lethal opportunities for the CDK cell cycle programs and the lead biologist for the cell panel screening program.
Alex Beatson, Ph.D.
Principal Research Scientist
Alex received a degree in mechatronics engineering from the University of Canterbury in New Zealand and a Ph.D. in machine learning from Princeton, where he worked in Ryan P. Adams's lab on ML to accelerate physics simulation and numerical design. He previously interned with the Google speech recognition team and Google Brain, consulted for private equity, and organized a NeurIPS workshop on ML for simulation and design.
Joe Nagamizo
Joe received his B.S. and M.S. degrees in Chemistry from UC San Diego. Prior to joining Genesis, he was part of the medicinal chemistry team at Inception Sciences for six years working on a variety of different targets. He has contributed to multiple patents, which include a dual EP2/4 antagonist currently undergoing Phase I clinical trials.
Sung-Wook Yi, Ph.D.
Woogie received his B.S. from GWNU in South Korea and Ph.D. from University of South Florida, then completed a postdoctoral training at UCLA. After a brief stint at Sumo Biosciences, he rejoined UCLA as a staff scientist. Over the years, he has worked on developing new therapeutic agents for Gram-positive pathogens, multiple sclerosis, and various cancers.
Wang Xu, CPA
Prior to joining Genesis, Wang was Controller of NovaBay Pharmaceuticals, where she was responsible for all accounting matters including SEC reporting, general accounting, and Sarbanes-Oxley compliance. Wang also served as Controller at AltheaDx, and as Assistant Controller at Oldcastle Materials. Wang started her career at Ernst & Young in Atlanta, serving audit clients in a variety of industries. Wang received a Masters of Accounting from UNC Chapel Hill.
Parvin Parineh
Executive Assistant
Parvin has spent the last decade in Silicon Valley supporting startups. She was on the founding team at MOCAP Analytics (sold to Sportradar) and Tapulous (sold to Disney). Prior to that she worked in finance and received a degree in Communications and Psychology from UC Davis.
James Schaeffer, Ph.D.
Business Advisor
James spent more than 28 years at Merck, where he was Executive Director of Licensing, responsible for identification and evaluation of all West Coast licensing opportunities.
Leonard Bell, M.D.
Chair of the Board of Directors
Dr. Bell was principal founder and CEO of Alexion Pharmaceuticals for 23 years, discovering and developing life-transforming therapies, and delivering them to patients in over 50 countries. In 2008, he accepted on behalf of Alexion the Prix Galien USA Award for Best Biotechnology Product, the industry's highest accolade for pharmaceutical R&D — equivalent to the Nobel Prize.
Genesis Therapeutics Hires Will McCarthy as Chief Business Officer
Genesis Therapeutics Secures $52M Series A, Led by Rock Springs Capital
Genesis Therapeutics raises $52M A round for its AI-focused drug discovery mission
Genesis Therapeutics Enters AI-driven, Multi-Target Drug Discovery Partnership with Genentech
Roche's James Sabry partners Genentech with Stanford spin­out Genesis Therapeutics
Genentech taps Stanford University spinout for AI drug discovery partnership
AI 50: America’s Most Promising Artificial Intelligence Companies
30 Under 30: Healthcare 2020
Five Questions with a16z’s Vijay Pande on AI and Making New Drugs
Genesis Therapeutics Raises $4.1M Seed, Led by Andreessen Horowitz
An Interview with Evan Feinberg